+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocannabinoid System Targeted Therapeutics Market, 2020-2030

  • PDF Icon


  • 280 Pages
  • April 2020
  • Region: Global
  • Roots Analysis
  • ID: 5116522


Chronic conditions, such as arthritis, cancer, diabetes, and heart disease are known to affect approximately 133 million Americans, representing over 40% of the total US population. This number is projected to grow to 157 million by the end of 2020. In addition, nearly 20 million Americans are estimated to suffer from some form of neurological disorder. Such conditions are generally characterized by a variety of complex symptoms, such as seizures, chronic pain and sleep disorders, for which medical science has not yet been able to identify an underlying cause. Drugs that offer symptomatic relief are the only treatment option currently available for such conditions. Traditionally, the go-to option has been opioids. However, this class of drugs has a high propensity of being abused. Moreover, there is a substantial body of evidence that proves that the long-term use of opioids leads to addiction, and eventually results in secondary substance use disorders. Cannabis has been shown to have properties similar to that of opioids, offering relief from a wide range of clinical symptoms. On the other hand, owing to its strong psychoactive properties, it is widely used as a recreational drug. As a result, there are stringent policies regulating the use of this substance, worldwide.

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Presently, cannabinoid derivatives, such as cannabidiol and cannabidivarin, have garnered the attention of the scientific community and are being investigated in mainstream clinical research initiatives. These molecules have been shown to modulate the endocannabinoid signaling system, primarily interacting with the CB1 and CB2 receptors. In fact, in 1985, the first synthetic cannabinoid drug, MARINOL®, was approved by the US FDA, for the treatment of nausea and vomiting, induced with chemotherapy. Recently, in 2018, EPIDIOLEX®, another cannabinoid derivative, was granted marketing authorization to be used to treat seizures associated with Lennox-Gastaut syndrome, or Dravet syndrome. Currently, there are several stakeholders in the pharmaceutical industry actively engaged in efforts to develop leads, derived from the Cannabis plant, as drugs to offer symptomatic relief across a diverse range of therapeutic areas. Of late, there has been substantial partnering activity in this field, as researchers/developers strive to forge strategic alliances, mostly to establish legitimate supply chains for raw material procurement, in order to support further research. Moreover, multiple start-ups, with backing from interested investors, have been established. As pioneers in this domain continue to achieve proof-of-concept, concerning the clinical benefits of this upcoming class of pharmacological molecules, we believe that this niche market is likely to witness substantial growth.

Scope of the Report

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.

In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, thrice daily and others) and target receptor (CB1, CB2, TRPV-1 and others). Additionally, the chapter includes information on drug developer(s), including information on year of establishment, company size, and location of headquarters.
  • Elaborate profiles of prominent endocannabinoid system targeted therapeutics developers that are engaged in the development of at least four development programs. Each profile features a brief overview of the company, its financial information (if available), product portfolio and an informed future outlook.
  • An in-depth analysis of nearly 600 grants that have been awarded to research institutes engaged in endocannabinoid system targeted projects, in the period between 2016 and 2020 (till January), including analysis based on important parameters, such as year of grant award, amount awarded, administration institute centre, funding institute centre, support period, type of grant application, purpose of grant award, grant mechanism, responsible study section, prominent program officers, and type of recipient organizations.
  • An analysis of the partnerships that have been established in the recent past, covering acquisitions, licensing agreements, product development and commercialization agreements, research agreements, clinical trial agreements, joint venture agreements and other relevant types of deals.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2016-2020, based on parameters, such as year of acquisition, type of acquisition, geographical location of the acquirer and the acquired company, key value drivers, and financial details of the deal (if available). In addition, the chapter evaluates the deal multiples of acquisitions specifically focused on endocannabinoid system targeted therapeutics, analysing them based on a number of parameters, namely annual revenues, number of employees and experience of the acquired company. Moreover, it presents a schematic world map representation of the geographical distribution of this activity, highlighting inter- and intracontinental deals.
  • An insightful chessboard analysis highlighting the most popular drug development strategies / paths adopted by various drug developers (with clinical candidates) in order to progress their lead drug candidates.

One of the key objectives of the report was to estimate the existing market size and the future opportunity for endocannabinoid system targeted therapeutics, over the next decade. Based on multiple parameters, such as target patient population, likely adoption and the annual treatment cost, we have provided informed estimates on the evolution of endocannabinoid system targeted therapeutics market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] key target receptors (CB1, CB2, and others) [B] different target therapeutic areas (autoimmune disorders, genetic disorders, neurological disorders and pain disorders) [C] routes of administration (oral and inhalation) and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain.

The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Oludare Odumosu (Chief Executive Officer, Zelira Therapeutics US)
  • Andrea Small-Howard (Chief Scientific Officer, GB Sciences)
  • Steeve Néron (Chief Operating Officer, Tetra Bio-Pharma)
  • Stephen Dahmer (Chief Medical Officer, Vireo Health)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Table of Contents

1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
3.1. Chapter Overview
3.2. Neuropharmacology and Working Mechanism of the Endocannabinoid System
3.3. Potential Therapeutic Applications of Cannabinoids
3.4. Legal Aspects and Regulations
3.5. Existing Challenges
3.6. Future of Cannabinoid Therapies
4.1. Chapter Overview
4.2. Drugs Targeting Endocannabinoid System: Marketed and Development Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Therapeutic Area
4.2.3. Analysis by Route of Administration
4.2.4. Analysis by Dosing Frequency
4.2.5. Analysis by Target Receptor
4.2.6. Grid Analysis: Distribution by Phase of Development, Target Therapeutic Area and Target Receptor
4.3. Endocannabinoid System Targeted Therapeutics: List of Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size and Geographical Location
4.4. List of Cannabis Suppliers
5.1. Chapter Overview
5.2. GW Pharmaceuticals
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Endocannabinoid Targeting Therapeutics Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Corbus Pharmaceuticals
5.3.1. Company Overview
5.3.2. Endocannabinoid Targeting Therapeutics Portfolio
5.3.3. Recent Developments and Future Outlook
5.4. Tilray
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Endocannabinoid Targeting Therapeutics Portfolio Recent Developments and Future Outlook
5.5. Pure Green
5.5.1. Company Overview
5.5.2. Endocannabinoid Targeting Therapeutics Portfolio
5.6. Tetra Bio-Pharma
5.6.1. Company Overview
5.6.2. Endocannabinoid Targeting Therapeutics Portfolio
5.6.3. Recent Developments and Future Outlook
5.7. Botanix Pharmaceuticals
5.7.1. Company Overview
5.7.2. Endocannabinoid Targeting Therapeutics Portfolio
5.7.3. Recent Developments and Future Outlook
5.8. Kalytera Therapeutics
5.8.1. Company Overview
5.8.2. Endocannabinoid Targeting Therapeutics Portfolio
5.8.3. Recent Developments and Future Outlook
5.9. Therapix Biosciences
5.9.1. Company Overview
5.9.2. Endocannabinoid Targeting Therapeutics Portfolio
5.9.3. Recent Developments and Future Outlook
5.10. Zelira Therapeutics
5.10.1. Company Overview
5.10.2. Endocannabinoid Targeting Therapeutics Portfolio
5.10.3. Recent Developments and Future Outlook
5.11. Avicanna
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Endocannabinoid Targeting Therapeutics Portfolio
5.11.4. Recent Developments and Future Outlook
5.12. GB Sciences
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Endocannabinoid Targeting Therapeutics Portfolio
5.12.4. Recent Developments and Future Outlook
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Endocannabinoid System Targeted Therapeutics: List of Grants Awarded by National Institutes of Health (NIH)
6.3.1. Analysis by Year of Grant Award
6.3.2. Analysis by Amount Awarded
6.3.3. Analysis by Administering Institute Center
6.3.4. Analysis by Funding Institute Center
6.3.5. Analysis by Support Period
6.3.6. Analysis by Funding Institute Center and Support Period
6.3.7. Analysis by Type of Grant Application
6.3.8. Analysis by Purpose of Grant Award
6.3.9. Analysis by Grant Mechanism
6.3.10. Word Cloud Analysis: Emerging Focus Areas
6.3.11. Analysis by Study Section Involved
6.3.12. Popular NIH Departments: Analysis by Number of Grants
6.3.13. Analysis by Types of Recipient Organizations
6.3.14. Prominent Program Officers: Analysis by Number of Grants
6.3.15. Popular Recipient Organizations: Analysis by Number of Grants
6.3.16. Regional Analysis of Recipient Organizations
7.1. Chapter Overview
7.2. Partnership Models
7.3. Endocannabinoid Targeted Therapeutics: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Partnership and Target Disease Indication
7.3.4. Analysis by Year of Partnership and Type of Partner
7.3.5. Most Active Players: Analysis by Number of Partnerships
7.3.6. Regional Analysis
7.3.7. Intercontinental and Intracontinental Agreements
8.1. Chapter Overview
8.2. Acquisition Models
8.3. Endocannabinoid Targeted Therapeutics: Mergers and Acquisitions
8.3.1. Cumulative Year-wise Trend
8.3.2. Analysis by Type of Acquisition
8.3.3. Year of Acquisitions and Deal Financials
8.3.4. Geographical Analysis of Mergers and Acquisitions
8.3.5. Ownership Change Matrix
8.3.6. Most Active Players: Analysis by Number of Acquisitions
8.3.7. Key Value Drivers
8.3.8. Valuation Analysis: Acquisition Deal Multiples
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Strategies Adopted by Late-Stage Drug Candidate Developers
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Endocannabinoid Targeted Therapeutics Market, 2020-2030
10.4. Global Endocannabinoid Targeted Therapeutics Market: Individual Product Sales Forecasts
10.4.1. EPIDIOLEX® (GW Pharmaceuticals) Target Patient Population Sales Forecast
10.4.2. Sativex® (GW Pharmaceuticals) Target Patient Population Sales Forecast
10.4.3. PPP011 (Caumz) Target Patient Population Sales Forecast
10.4.4. Lenabasum Target Patient Population Sales Forecast
10.4.5. CBD Oil Capsules Target Patient Population Sales Forecast
10.4.6. CannEpil™ Target Patient Population Sales Forecast
10.5. Global Endocannabinoid System Targeted Therapeutics Market, 2020-2030
10.6. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Region, 2020-2030
10.6.1. Endocannabinoid System Targeted Therapeutics Market in North America, 2020-2030
10.6.2. Endocannabinoid System Targeted Therapeutics Market in Europe, 2020-2030
10.6.3. Endocannabinoid System Targeted Therapeutics Market in Asia-Pacific, 2020-2030
10.6.4. Endocannabinoid System Targeted Therapeutics Market in Rest of the World, 2020-2030
10.7. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Target Therapeutic Area, 2020-2030
10.7.1. Global Endocannabinoid System Targeted Therapeutics Market for Autoimmune Diseases, 2020-2030
10.7.2. Global Endocannabinoid System Targeted Therapeutics Market for Genetic Disorders, 2020-2030
10.7.3. Global Endocannabinoid System Targeted Therapeutics Market for Neurological Disorders, 2020-2030
10.7.4. Global Endocannabinoid System Targeted Therapeutics Market for Pain Disorders, 2020-2030
10.8. Global Endocannabinoid System Targeted Therapeutics Market: Distribution by Route of Administration
10.8.1. Global Endocannabinoid System Targeted Therapeutics Market for Oral Therapies, 2020-2030
10.8.5. Global Endocannabinoid System Targeted Therapeutics Market for Inhalation Therapies, 2020-2030
12.1. Chapter Overview
12.2 Zelira Therapeutics US
12.2.1. Company Snapshot
12.2.2. Interview Transcript: Oludare Odumosu, Chief Executive Officer
12.3. GB Sciences
12.3.1. Company Snapshot
12.3.2. Interview Transcript: Andrea Small-Howard, Chief Scientific Officer
12.4. Tetra Bio-Pharma
12.4.1. Company Snapshot
12.4.2. Interview Transcript: Steeve Néron, Chief Operating Officer
12.5 Vireo Health
12.5.1. Company Snapshot
12.5.2. Interview Transcript: Stephen Dahmer, Chief Medical Officer

Companies Mentioned

  • Abide Therapeutics
  • Aelis Farma
  • Agrima Botanicals
  • Albany Molecular Research
  • Alkem Laboratories
  • Alliqua BioMedical
  • Alternavida
  • Altus Formulation
  • Anandia Laboratories
  • Aphios
  • Aphria
  • Aptus Clinical
  • Arena Pharmaceuticals
  • Artelo Biosciences
  • Assuta Medical Centers
  • Aurora Cannabis
  • Authentic Brands Group
  • Avicanna
  • AXIM Biotechnologies
  • Azevedos Indústria Farmacêutica
  • Battelle
  • Bausch Health
  • BC Northern Lights
  • Beckley Canopy Therapeutics
  • Beetlebung Pharma
  • Bird Rock Bio
  • Botanix Pharmaceuticals
  • C3 Cannabinoid Compound Company
  • Canapalife Group
  • Cannabics Pharmaceuticals
  • Cannabis Science
  • CannaKids
  • Cannamedical Pharma
  • Cannara Biotech
  • CanniMed Therapeutics
  • CannRx
  • Canntab Therapeutics
  • Canopy Growth
  • CanvasRx
  • Cara Therapeutics
  • Catalent Pharma Solutions
  • Champignon Brands
  • Chemi Pharmaceutical
  • Children’s Hospital of Philadelphia
  • Ci Therapeutics
  • Columbia University
  • Constance Therapeutics
  • Corbus Pharmaceuticals
  • Cowen
  • Cura Cannabis Solutions
  • CURE Pharmaceutical
  • Curtin University
  • CV Sciences
  • Dana-Farber Cancer Institute
  • DayaCann
  • Delivra
  • ebbu
  • Echo Pharmaceuticals
  • Emerald Bioscience
  • Emerald Clinics
  • Emilia Cosmetics
  • EnWave
  • Ethicann Pharmaceuticals
  • FDI Clinical Research
  • FoliuMed
  • Four20
  • FSD Pharma
  • FutureNeuro
  • GB Sciences
  • GE Healthcare
  • GenCanna
  • GlaxoSmithKline
  • Greenbelt Greenhouse
  • GreenLight Medicines
  • GW Pharmaceuticals
  • H2 Biopharma
  • Harvest One Cannabis
  • Health House
  • Heavenly Rx
  • Hempco Food and Fiber
  • Hospital del Mar Medical Research Institute
  • Impression Healthcare
  • InMed Pharmaceuticals
  • INSYS Therapeutics
  • IntelGenx Technologies
  • InterCure
  • Inversago Pharma
  • IsCann Group
  • iX Biopharma
  • Janssen Pharmaceuticals
  • Jenrin Discovery
  • Kaken Pharmaceutical
  • Kalytera Therapeutics
  • Kamada
  • Kannalife Sciences
  • Khiron Life Sciences
  • KISS Industries
  • Knop Laboratorios
  • Larssen (acquired by Aurora Cannabis)
  • LiveWell Cana da
  • LSU AgCenter
  • Lundbeck
  • LYPHE Group
  • MAKScientific
  • MannKind Corporation
  • Medipure Pharmaceuticals
  • MedLab Clinical
  • MGC Pharmaceuticals
  • Michigan State University
  • Mitacs
  • Montefiore Medical Center
  • Nanomerics
  • National and Kapodistrian University of Athens
  • National Institute on Drug Abuse
  • National Research Council of Canada
  • Natura Naturals
  • NEEKA Health Canada
  • NEOMED Institute
  • Neptune Technologies & Bioressources
  • NettaGrowth International
  • NHS Industries
  • Niagara College
  • Noramco
  • Novartis
  • Onegevity Health
  • 126.   Oregon   01
  • Ovensa
  • OWC Pharmaceutical Research
  • Panax Pharma
  • Panag Pharma
  • Parkinson's Foundation
  • Pascal Biosciences
  • Pedanios
  • Peloton Pharmaceuticals
  • Pharmascience
  • Pharmaseed
  • Pharmastrip
  • PharmHouse
  • Phivida
  • Phytecs
  • PhytoPain Pharma
  • PhytoTech Therapeutics
  • Pompeu Fabra University
  • Prairie Plant Systems
  • Prismic Pharmaceuticals
  • Privateer
  • ProCaps Laboratories
  • Pure Green
  • Purisys
  • QPS Netherlands
  • Radient Technologies
  • ReLeaf Europe
  • Revive Therapeutics
  • Rhodes Technologies
  • Royal Melbourne Institute of Technology
  • Saint Vincent Hospital
  • Sandoz
  • Santa Marta Golden Hemp
  • Santé Cannabis
  • Sanyal Biotechnology
  • Sativa Group
  • SciCann Therapeutics
  • Serina Therapeutics
  • Shoppers Drug Mart
  • Sigma Analytical Services
  • Solarvest BioEnergy
  • South Carolina Research Foundation
  • Spectrum Therapeutics
  • Stellenbosch University
  • STERO Biotechs
  • Stevens Green
  • Stony Brook University
  • Syngene International
  • Talent Biotechs
  • Tassili Life Sciences
  • Teewinot Life Sciences
  • Tel Aviv Sourasky Medical Center
  • Telethon Kids Institute
  • Tetra Bio-Pharma
  • T-G Initiatives
  • THC Global Group
  • The Hebrew University of Jerusalem
  • 184.   The Ontario Lung   Association
  • The Supreme Cannabis Company
  • The University of Auckland
  • The University of British Columbia
  • The University of Mississippi
  • The University of Seville
  • The University of Western Australia
  • The Valens
  • Therapix Biosciences
  • Thorne Research  
  • Tilray
  • True North Cannabis
  • UC San Diego School of Medicine
  • Universidad Complutense de Madrid
  • University of Bordeaux
  • University of Central Florida
  • University of Guelph
  • University of Toronto
  • University of Washington
  • Urban Cultivator
  • Veritas Pharma
  • Vitality Biopharma
  • Vitiprints
  • WeedMD
  • Wisconsin Alumni Research Foundation
  • World-Class Extractions
  • Yale University
  • Zelira Therapeutics
  • Zenabis
  • Zynerba Pharmaceuticals